Literature DB >> 11836160

Clinical phenotypes and molecular characterization of Hb H-Paksé disease.

Vip Viprakasit1, Voravarn S Tanphaichitr, Parichat Pung-Amritt, Siripan Petrarat, Lerlugsn Suwantol, Chris Fisher, Douglas R Higgs.   

Abstract

BACKGROUND AND OBJECTIVES: Hemoglobin Constant Spring (Hb CS), caused by a termination codon mutation (TAA-->CAA) in the a2 gene, is the most common non-deletional type of a thalassemia in Southeast Asia. This mutation can most easily be detected by loss of an MseI-restriction site (T/TAA) spanning the termination codon. Recently, we sequenced the a globin genes from patients with a thalassemia in whom this MseI site was absent. This revealed, a previously described termination codon mutation (TAA-->TAT) associated with Hb Paksé. This prompted us to re-evaluate the molecular basis of a thalassaemia in other Thai patients with non-deletional types of Hb H disease. DESIGN AND METHODS: DNA samples from 30 patients, previously diagnosed as having Hb H-CS disease, were characterized by direct genomic sequencing and by using a mismatched polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Clinical and hematologic data were assessed.
RESULTS: Hemoglobin electrophoresis in almost all 30 unrelated patients with non-deletional a thalassemia revealed a slow migrating band resembling Hb CS. Five of these patients were found to have Hb H-Paksé disease and the remainder had Hb H-CS disease. Comparing the hematology in patients with these two genotypes, no significant differences were found except that the proportion of Hb H was higher in patients with Hb H-Paksé disease. INTERPRETATION AND
CONCLUSIONS: These results suggest that termination codon mutations may have been previously misidentified in many cases of non-deletional Hb H disease. Findings from six unrelated families described in this study suggest that the proportion of patients with the Hb Paksé mutation might be underestimated and that this mutation could be prevalent in Southeast Asia. Analysis of mismatched-PCR-RFLP, described here, was shown to provide an unequivocal diagnosis and will be applicable in population screening programs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836160

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  8 in total

1.  Hemoglobin Pakse: presence on red blood cell membrane and detection by polymerase chain reaction-single-strand conformational polymorphism.

Authors:  Chairat Turbpaiboon; Atchasai Siritantikorn; Wanna Thongnoppakhun; Duangkamon Bunditworapoom; Chanin Limwongse; Pa-thai Yenchitsomanus; Noppadol Siritanaratkul; Prapon Wilairat
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

2.  Molecular characterisation of Haemoglobin Constant Spring and Haemoglobin Quong Sze with a Combine-Amplification Refractory Mutation System.

Authors:  Yong-Chui Wee; Kim-Lian Tan; Kek-Heng Chua; Elizabeth George; Jin-Ai Mary Anne Tan
Journal:  Malays J Med Sci       Date:  2009-07

3.  Iron deficiency anemia interfering the diagnosis of compound heterozygosity for Hb constant spring and Hb Paksé: The first case report.

Authors:  Thita Chiasakul; Noppacharn Uaprasert
Journal:  J Clin Lab Anal       Date:  2017-02-28       Impact factor: 2.352

Review 4.  Haemoglobinopathies in southeast Asia.

Authors:  Suthat Fucharoen; Pranee Winichagoon
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

5.  Tertiary structural analysis of the elongated part of an abnormal hemoglobin, hemoglobin Pakse.

Authors:  Viroj Wiwanitkit
Journal:  Int J Nanomedicine       Date:  2006

6.  DNA studies are necessary for accurate patient diagnosis in compound heterozygosity for Hb Adana (HBA2:c.179>A) with deletional or nondeletional α-thalassaemia.

Authors:  Jin Ai Mary Anne Tan; Siew Leng Kho; Chin Fang Ngim; Kek Heng Chua; Ai Sim Goh; Seoh Leng Yeoh; Elizabeth George
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

Review 7.  Treating iron overload in patients with non-transfusion-dependent thalassemia.

Authors:  Ali T Taher; Vip Viprakasit; Khaled M Musallam; M Domenica Cappellini
Journal:  Am J Hematol       Date:  2013-03-08       Impact factor: 10.047

Review 8.  When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia.

Authors:  A T Taher; A Radwan; V Viprakasit
Journal:  Vox Sang       Date:  2014-10-07       Impact factor: 2.144

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.